AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03040141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of VIS410
Description: Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
Study NCT03040141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of placebo in addition to oseltamivir
Study NCT04296760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rectal water-contrast transvaginal ultrasonography
Description: Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
Study NCT04296760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sonovaginography
Description: Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
Study NCT00647764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422 Mesylate Hsp90 inhibitor
Description: dose escalated, tablets twice a week; undetermined duration until disease progression
Study NCT04602403 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rigid ureteroscopy
Description: endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
Study NCT04602403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rigid ureteroscopy
Description: endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
Study NCT00626444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C
Description: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
Study NCT01863823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin and Tetracyclines
Description: 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
Study NCT01863823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mouth washing
Description: Two time washing mouth per day
Study NCT00002998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00002998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT02364908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: therapeutic education
Description: This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
Study NCT04268186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.
Study NCT04268186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
Study NCT04268186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.
Study NCT04268186 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
Study NCT01596803 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Taking of blood
Description: Taking venous blood samples to analyse oxidant stress
Study NCT01596803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taking of blood
Description: Taking venous blood samples to analyse oxidant stress
Study NCT01596803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: needle biopsy of the vastus lateralis muscle
Description: T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
Study NCT01596803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: needle biopsy of the vastus lateralis muscle
Description: T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
Study NCT01596803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit C Vit E Zn Se
Description: T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
Study NCT01596803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vit E Placebo Vit C Zn Se
Description: venous blood samples and needle biopsy
Study NCT01439516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
Study NCT01903460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Study NCT01903460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00510835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Goal Directed Therapy (EGDT)
Description: Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
Study NCT00510835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized Standard Care (PSC)
Description: Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
Study NCT00510835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
Study NCT02700477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fenugreek seeds extract
Description: Fenugreek seed extract 500mg, BD
Study NCT02700477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing Dicalcium Phosphate 500mg, BD
Study NCT03268772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD and IFO
Description: PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
Study NCT02819921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate 100mg
Description: Pristiq 100mg
Study NCT02819921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate 50mg
Description: Pristiq 50mg
Study NCT02819921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03050801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways
Study NCT00102466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT00102466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Study NCT00102466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00102466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03572946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted prostate biopsy
Description: MRI-guided targeted prostate biopsy
Study NCT03572946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard biopsy
Description: Transperineal ultrasound guided prostate biopsy(SB).
Study NCT03691909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences autologous adipose-derived mesenchymal stem cells
Study NCT02883569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open or endoscopic discectomy
Description: FDA approved surgical procedures
Study NCT02883569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural block
Description: epidural block
Study NCT02883569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: educated exercise
Study NCT02883569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: educated exercise
Study NCT02883569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac
Description: FDA approved medication such as ibuprofen, naxoprofen etc.
Study NCT02883569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac
Description: FDA approved medication such as ibuprofen, naxoprofen etc.
Study NCT02883569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: decompression
Description: FDA approved surgical procedure such as lamiectom and, laminotomy
Study NCT02883569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: instrumentation and fusion
Description: FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
Study NCT02883569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: codeine, oxycontine, IRcodone, Tramadol
Description: FDA approved opioid drug such as codeine, oxycontin, IRcodon
Study NCT02883569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine, oxycontine, IRcodone, Tramadol
Description: FDA approved opioid drug such as codeine, oxycontin, IRcodon
Study NCT02883569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural adhesiolysis
Description: FDA approved epidural adhesiolysis with catheter or endoscope
Study NCT02883569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural adhesiolysis
Description: FDA approved epidural adhesiolysis with catheter or endoscope
Study NCT02234843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
Study NCT02234843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
Study NCT02918227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Search retrograde ejaculation
Description: Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
Study NCT00178126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Protection Wheelchair Seat Cushion
Description: Cushion receiving CMS code for Skin Protection Wheelchair Cushion
Study NCT00178126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Segmented Foam Wheelchair Seat Cushion
Description: General use class wheelchair seat cushion
Study NCT02845362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sydney Swallow Questionnaire
Description: The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
Study NCT02822144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Study NCT02822144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Study NCT02822144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT02822144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT02822144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT03718130 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Description: The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study NCT03718130 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
Description: The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study NCT02234843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care
Study NCT05356286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural electrical stimulation
Description: Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
Study NCT03164486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-αvβ6-BP
Description: Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
Study NCT01576341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 epoetin alfa (Sandoz)
Description: Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
Study NCT03718130 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Description: The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study NCT03718130 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
Description: The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study NCT03649542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluidotherapy plus exercise
Description: The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
Study NCT04227470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection
Description: Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
Study NCT03586765 — intervention group
Intervention type: OTHER
Intervention: Female urinary incontinence
Description: Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
Study NCT01844765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Study NCT03810677 — intervention group
Intervention type: DEVICE
Intervention: ELVeS® Radial® 2ring slim fiber
Description: Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
Study NCT04038502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
Study NCT04038502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
Study NCT02211794 — intervention group
Intervention type: OTHER
Intervention: data collection
Study NCT02429635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My exercise
Description: Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan
Study NCT05010603 — intervention group
Intervention type: GENETIC
Intervention: Blood Draw
Description: Collection of blood samples for genetic testing
Study NCT04190459 — intervention group
Intervention type: PROCEDURE
Intervention: LSG
Description: Bariatric surgery
Study NCT04190459 — intervention group
Intervention type: PROCEDURE
Intervention: LRYGB
Description: Bariatric surgery
Study NCT06524102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Activated Cell Sorting
Description: The MACS® ART Annexin V System has been designed for the in vitro elimination of apoptotic human spermatozoa in fresh, cryopreserved or otherwise manipulated semen samples. Samples processed by this technique can be subsequently used in any assisted reproduction procedure.~Annexin V recognizes externalized phosphatidylserine (ePS) on the plasma membrane of apoptotic spermatozoa. Depletion of the altered sperm begins with magnetic tagging of the sperm. The system selectively retains unwanted sperm by utilizing the natural ability of annexin V to recognize the ePS on the plasma membrane of the altered sperm, because annexin V is conjugated to metal microspheres. The labeled cells pass through a separation column in a fixed magnetic field. Unwanted (altered) spermatozoa are selectively retained in the separation column. Unlabeled spermatozoa pass through the column where they are collected for later use.
Study NCT01431612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol administration
Description: 50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
Study NCT01431612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: 0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
Study NCT01431612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer´s solution
Description: Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
Study NCT02203734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate Pressure Massage
Description: The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.